logo-loader
viewGenedrive PLC

Genedrive's David Budd details launch of its unique coronavirus test kits and plans for first sales

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version of the test which can be done outside of hospitals. Budd also discusses WHO approval received for its HCV test as well as new distribution arrangements for its infant deafness test.

Quick facts: Genedrive PLC

Price: 109 GBX

AIM:GDR
Market: AIM
Market Cap: £56.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 heads lower as UK monthly borrowing hits record...

Headlines from the Proactive UK newsroom. The FTSE 100 headed lower going into the bank holiday weekend on concern over the spat between China and US over Hong Kong. The blue-chip index was 110 points lower at 5,904. UK monthly borrowing hit a record £62.1bn in April as the government...

on 22/5/20

2 min read